In a surprising development, the U.S. Department of Justice filed a brief telling the U.S. Supreme Court that it wants to end a closely watched whistleblower lawsuit filed against Gilead Sciences (GILD) because it is “not in the public interest.”

Moreover, the Justice Department further indicated it would seek to dismiss the case if the Supreme Court were to send it back for further review by a federal circuit court, even though the agency appeared to support the legal theory underpinning the case.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Question to our scribe – what if any action did FDA take against Gilead products in light of the contamination? None that i recall but “who am I?”

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy